Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease

M. Britschgi, C. E. Olin, H. T. Johns, Y. Takeda-Uchimura, M. C. Lemieux, K. Rufibach, J. Rajadas, H. Zhang, B. Tomooka, W. H. Robinson, C. M. Clark, A. M. Fagan, D. R. Galasko, D. M. Holtzman, M. Jutel, Jeffrey Kaye, C. A. Lemere, J. Leszek, G. Li, E. R. PeskindJoseph Quinn, J. A. Yesavage, J. A. Ghiso, T. Wyss-Coray

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

A number of distinct β-amyloid (Aβ) variants or multimers have been implicated in Alzheimer's disease (AD), and antibodies recognizing such peptides are in clinical trials. Humans have natural Aβ-specific antibodies, but their diversity, abundance, and function in the general population remain largely unknown. Here, we demonstrate with peptide microarrays the presence of natural antibodies against known toxic Aβ and amyloidogenic non-Aβ species in plasma samples and cerebrospinal fluid of AD patients and healthy controls aged 21-89 years. Antibody reactivity was most prominent against oligomeric assemblies of Aβ and pyroglutamate or oxidized residues, and IgGs specific for oligomeric preparations of Aβ1-42 in particular declined with age and advancing AD. Most individuals showed unexpected antibody reactivities against peptides unique to autosomal dominant forms of dementia (mutant Aβ, ABri, ADan) and IgGs isolated from plasma of AD patients or healthy controls protected primary neurons from Aβ toxicity. Aged vervets showed similar patterns of plasma IgG antibodies against amyloid peptides, and after immunization with Aβ the monkeys developed high titers not only against Aβ peptides but also against ABri and ADan peptides. Our findings support the concept of conformation-specific, cross-reactive antibodies that may protect against amyloidogenic toxic peptides. If a therapeutic benefit of Aβ antibodies can be confirmed in AD patients, stimulating the production of such neuroprotective antibodies or passively administering them to the elderly population may provide a preventive measure toward AD.

Original languageEnglish (US)
Pages (from-to)12145-12150
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume106
Issue number29
DOIs
StatePublished - Jul 21 2009

Fingerprint

Alzheimer Disease
Peptides
Antibodies
Abrus
Poisons
Amyloid
Antibody Diversity
Pyrrolidonecarboxylic Acid
Population
Haplorhini
Cerebrospinal Fluid
Dementia
Immunization
Immunoglobulin G
Clinical Trials
Neurons

ASJC Scopus subject areas

  • General

Cite this

Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. / Britschgi, M.; Olin, C. E.; Johns, H. T.; Takeda-Uchimura, Y.; Lemieux, M. C.; Rufibach, K.; Rajadas, J.; Zhang, H.; Tomooka, B.; Robinson, W. H.; Clark, C. M.; Fagan, A. M.; Galasko, D. R.; Holtzman, D. M.; Jutel, M.; Kaye, Jeffrey; Lemere, C. A.; Leszek, J.; Li, G.; Peskind, E. R.; Quinn, Joseph; Yesavage, J. A.; Ghiso, J. A.; Wyss-Coray, T.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, No. 29, 21.07.2009, p. 12145-12150.

Research output: Contribution to journalArticle

Britschgi, M, Olin, CE, Johns, HT, Takeda-Uchimura, Y, Lemieux, MC, Rufibach, K, Rajadas, J, Zhang, H, Tomooka, B, Robinson, WH, Clark, CM, Fagan, AM, Galasko, DR, Holtzman, DM, Jutel, M, Kaye, J, Lemere, CA, Leszek, J, Li, G, Peskind, ER, Quinn, J, Yesavage, JA, Ghiso, JA & Wyss-Coray, T 2009, 'Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease', Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 29, pp. 12145-12150. https://doi.org/10.1073/pnas.0904866106
Britschgi, M. ; Olin, C. E. ; Johns, H. T. ; Takeda-Uchimura, Y. ; Lemieux, M. C. ; Rufibach, K. ; Rajadas, J. ; Zhang, H. ; Tomooka, B. ; Robinson, W. H. ; Clark, C. M. ; Fagan, A. M. ; Galasko, D. R. ; Holtzman, D. M. ; Jutel, M. ; Kaye, Jeffrey ; Lemere, C. A. ; Leszek, J. ; Li, G. ; Peskind, E. R. ; Quinn, Joseph ; Yesavage, J. A. ; Ghiso, J. A. ; Wyss-Coray, T. / Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. In: Proceedings of the National Academy of Sciences of the United States of America. 2009 ; Vol. 106, No. 29. pp. 12145-12150.
@article{bb79b9819164444d9374f62aafcae07f,
title = "Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease",
abstract = "A number of distinct β-amyloid (Aβ) variants or multimers have been implicated in Alzheimer's disease (AD), and antibodies recognizing such peptides are in clinical trials. Humans have natural Aβ-specific antibodies, but their diversity, abundance, and function in the general population remain largely unknown. Here, we demonstrate with peptide microarrays the presence of natural antibodies against known toxic Aβ and amyloidogenic non-Aβ species in plasma samples and cerebrospinal fluid of AD patients and healthy controls aged 21-89 years. Antibody reactivity was most prominent against oligomeric assemblies of Aβ and pyroglutamate or oxidized residues, and IgGs specific for oligomeric preparations of Aβ1-42 in particular declined with age and advancing AD. Most individuals showed unexpected antibody reactivities against peptides unique to autosomal dominant forms of dementia (mutant Aβ, ABri, ADan) and IgGs isolated from plasma of AD patients or healthy controls protected primary neurons from Aβ toxicity. Aged vervets showed similar patterns of plasma IgG antibodies against amyloid peptides, and after immunization with Aβ the monkeys developed high titers not only against Aβ peptides but also against ABri and ADan peptides. Our findings support the concept of conformation-specific, cross-reactive antibodies that may protect against amyloidogenic toxic peptides. If a therapeutic benefit of Aβ antibodies can be confirmed in AD patients, stimulating the production of such neuroprotective antibodies or passively administering them to the elderly population may provide a preventive measure toward AD.",
author = "M. Britschgi and Olin, {C. E.} and Johns, {H. T.} and Y. Takeda-Uchimura and Lemieux, {M. C.} and K. Rufibach and J. Rajadas and H. Zhang and B. Tomooka and Robinson, {W. H.} and Clark, {C. M.} and Fagan, {A. M.} and Galasko, {D. R.} and Holtzman, {D. M.} and M. Jutel and Jeffrey Kaye and Lemere, {C. A.} and J. Leszek and G. Li and Peskind, {E. R.} and Joseph Quinn and Yesavage, {J. A.} and Ghiso, {J. A.} and T. Wyss-Coray",
year = "2009",
month = "7",
day = "21",
doi = "10.1073/pnas.0904866106",
language = "English (US)",
volume = "106",
pages = "12145--12150",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "29",

}

TY - JOUR

T1 - Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease

AU - Britschgi, M.

AU - Olin, C. E.

AU - Johns, H. T.

AU - Takeda-Uchimura, Y.

AU - Lemieux, M. C.

AU - Rufibach, K.

AU - Rajadas, J.

AU - Zhang, H.

AU - Tomooka, B.

AU - Robinson, W. H.

AU - Clark, C. M.

AU - Fagan, A. M.

AU - Galasko, D. R.

AU - Holtzman, D. M.

AU - Jutel, M.

AU - Kaye, Jeffrey

AU - Lemere, C. A.

AU - Leszek, J.

AU - Li, G.

AU - Peskind, E. R.

AU - Quinn, Joseph

AU - Yesavage, J. A.

AU - Ghiso, J. A.

AU - Wyss-Coray, T.

PY - 2009/7/21

Y1 - 2009/7/21

N2 - A number of distinct β-amyloid (Aβ) variants or multimers have been implicated in Alzheimer's disease (AD), and antibodies recognizing such peptides are in clinical trials. Humans have natural Aβ-specific antibodies, but their diversity, abundance, and function in the general population remain largely unknown. Here, we demonstrate with peptide microarrays the presence of natural antibodies against known toxic Aβ and amyloidogenic non-Aβ species in plasma samples and cerebrospinal fluid of AD patients and healthy controls aged 21-89 years. Antibody reactivity was most prominent against oligomeric assemblies of Aβ and pyroglutamate or oxidized residues, and IgGs specific for oligomeric preparations of Aβ1-42 in particular declined with age and advancing AD. Most individuals showed unexpected antibody reactivities against peptides unique to autosomal dominant forms of dementia (mutant Aβ, ABri, ADan) and IgGs isolated from plasma of AD patients or healthy controls protected primary neurons from Aβ toxicity. Aged vervets showed similar patterns of plasma IgG antibodies against amyloid peptides, and after immunization with Aβ the monkeys developed high titers not only against Aβ peptides but also against ABri and ADan peptides. Our findings support the concept of conformation-specific, cross-reactive antibodies that may protect against amyloidogenic toxic peptides. If a therapeutic benefit of Aβ antibodies can be confirmed in AD patients, stimulating the production of such neuroprotective antibodies or passively administering them to the elderly population may provide a preventive measure toward AD.

AB - A number of distinct β-amyloid (Aβ) variants or multimers have been implicated in Alzheimer's disease (AD), and antibodies recognizing such peptides are in clinical trials. Humans have natural Aβ-specific antibodies, but their diversity, abundance, and function in the general population remain largely unknown. Here, we demonstrate with peptide microarrays the presence of natural antibodies against known toxic Aβ and amyloidogenic non-Aβ species in plasma samples and cerebrospinal fluid of AD patients and healthy controls aged 21-89 years. Antibody reactivity was most prominent against oligomeric assemblies of Aβ and pyroglutamate or oxidized residues, and IgGs specific for oligomeric preparations of Aβ1-42 in particular declined with age and advancing AD. Most individuals showed unexpected antibody reactivities against peptides unique to autosomal dominant forms of dementia (mutant Aβ, ABri, ADan) and IgGs isolated from plasma of AD patients or healthy controls protected primary neurons from Aβ toxicity. Aged vervets showed similar patterns of plasma IgG antibodies against amyloid peptides, and after immunization with Aβ the monkeys developed high titers not only against Aβ peptides but also against ABri and ADan peptides. Our findings support the concept of conformation-specific, cross-reactive antibodies that may protect against amyloidogenic toxic peptides. If a therapeutic benefit of Aβ antibodies can be confirmed in AD patients, stimulating the production of such neuroprotective antibodies or passively administering them to the elderly population may provide a preventive measure toward AD.

UR - http://www.scopus.com/inward/record.url?scp=67749122581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67749122581&partnerID=8YFLogxK

U2 - 10.1073/pnas.0904866106

DO - 10.1073/pnas.0904866106

M3 - Article

C2 - 19581601

AN - SCOPUS:67749122581

VL - 106

SP - 12145

EP - 12150

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 29

ER -